Cyteir Therapeutics Inc

NASDAQ CYT

Download Data

Cyteir Therapeutics Inc Gross Profit to Fixed Assets Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023

Cyteir Therapeutics Inc Gross Profit to Fixed Assets Ratio 5 year CAGR is NA for the Trailing 12 Months (TTM) ending September 30, 2023. The Gross Profit to Fixed Assets Ratio measures the gross profit generated per dollar of fixed assets (property, plant, and equipment). It indicates how efficiently a company utilizes its fixed assets to generate gross profit. A higher ratio suggests better gross profit generation from fixed assets, indicating improved operational efficiency and potentially higher profitability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: CYT

Cyteir Therapeutics Inc

CEO Mr. Joseph S. Zakrzewski
IPO Date June 18, 2021
Location United States
Headquarters 128 Spring Street, Lexington, MA, United States, 02421
Employees 46
Sector Healthcare
Industry Biotechnology
Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email